| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics
|
Aug 11, 2026 | BUY |
Buy
+18.7% avg upside
10 analysts
|
$9.00
103.53% Upside
|
· | · |
|
INGN
Inogen
|
Aug 07, 2026 | BUY |
Buy
+317.4% avg upside
7 analysts
|
$12.00
103.04% Upside
|
-1.3% | · |
|
RMD
Resmed
|
Aug 07, 2026 | HOLD |
Buy
+2.2% avg upside
27 analysts
|
— | +6.6% | · |
|
ICUI
ICU Medical
|
Aug 07, 2026 | BUY |
Strong Buy
-2.8% avg upside
9 analysts
|
$187.00
2.26% Upside
|
+0.0% | · |
|
AORT
Artivion
|
Aug 07, 2026 | BUY |
Strong Buy
+48.6% avg upside
8 analysts
|
$44.00
61.24% Upside
|
+0.0% | · |
|
ENOV
Enovis
|
Aug 06, 2026 | BUY |
Strong Buy
+172.7% avg upside
39 analysts
|
$52.00
110.67% Upside
|
+1.1% | · |
|
PSNL
Personalis
|
Aug 06, 2026 | HOLD |
Strong Buy
+2.7% avg upside
11 analysts
|
— | +7.6% | · |
|
ESTA
Establishment Labs Holdings
|
Aug 06, 2026 | BUY |
Strong Buy
+20.0% avg upside
12 analysts
|
$95.00
27.93% Upside
|
-6.2% | · |
|
TFX
Teleflex
|
Aug 06, 2026 | BUY |
Buy
+38.4% avg upside
20 analysts
|
$159.00
19.45% Upside
|
-3.9% | · |
|
STE
Steris
|
Aug 06, 2026 | HOLD |
Strong Buy
+0.5% avg upside
10 analysts
|
— | +3.1% | · |
|
HAE
Haemonetics
|
Aug 06, 2026 | HOLD |
Buy
-13.7% avg upside
17 analysts
|
— | +3.3% | · |
|
LIVN
LivaNova
|
Aug 05, 2026 | BUY |
Strong Buy
+4.4% avg upside
15 analysts
|
$93.00
20.23% Upside
|
+3.4% | · |
|
INMD
InMode
|
Aug 05, 2026 | HOLD |
Buy
+28.2% avg upside
9 analysts
|
— | +0.1% | · |
|
ZBH
Zimmer Biomet Holdings
|
Aug 05, 2026 | HOLD |
Buy
+17.5% avg upside
38 analysts
|
— | -0.3% | · |
|
KIDS
OrthoPediatrics
|
Aug 05, 2026 | BUY |
Strong Buy
+29.8% avg upside
10 analysts
|
$35.00
44.97% Upside
|
+7.1% | · |
|
TMDX
TransMedics Group
|
Aug 03, 2026 | BUY |
Strong Buy
+16.6% avg upside
15 analysts
|
$106.00
22.74% Upside
|
+6.7% | · |
|
VCYT
Veracyte
|
Jul 31, 2026 | BUY |
Strong Buy
+9.3% avg upside
19 analysts
|
$69.00
49.32% Upside
|
-2.4% | · |
|
MMSI
Merit Medical Systems
|
Jul 31, 2026 | BUY |
Strong Buy
+8.9% avg upside
15 analysts
|
$101.00
10.45% Upside
|
+4.7% | · |
|
SYK
Stryker
|
Jul 31, 2026 | BUY |
Strong Buy
+6.1% avg upside
37 analysts
|
$418.00
20.47% Upside
|
+6.2% | · |
|
CNMD
Conmed
|
Jul 30, 2026 | HOLD |
Hold
+31.5% avg upside
12 analysts
|
— | +4.6% | · |
|
NEO
NeoGenomics
|
Jul 29, 2026 | BUY |
Strong Buy
+3.8% avg upside
18 analysts
|
$19.00
15.03% Upside
|
+6.6% | · |
|
BSX
Boston Scientific
|
Jul 29, 2026 | BUY |
Strong Buy
+32.8% avg upside
38 analysts
|
$57.00
11.65% Upside
|
+11.7% | · |
|
ATRC
Atricure
|
Jul 24, 2026 | BUY |
Strong Buy
+8.1% avg upside
13 analysts
|
$45.00
6.20% Upside
|
+22.8% | · |
|
MDT
Medtronic
|
Jun 17, 2026 | BUY |
Buy
+6.9% avg upside
38 analysts
|
$101.00
12.18% Upside
|
+15.6% | · |
|
LUCD
Lucid Diagnostics
|
May 14, 2026 | BUY |
Strong Buy
+403.7% avg upside
8 analysts
|
$3.00
210.56% Upside
|
-3.9% | · |
|
PEN
Penumbra
|
Feb 25, 2026 | HOLD |
Buy
+1.2% avg upside
23 analysts
|
— | -3.6% | · |
|
TSE:SWA
Sarama Resources
|
Apr 05, 2024 | HOLD |
Hold
1 analyst
|
— | +100.0% | · |
|
GMED
Globus Medical
|
May 05, 2021 | BUY |
Strong Buy
+7.9% avg upside
24 analysts
|
$82.00
4.00% Downside
|
-8.3% | · |
|
SIBN
SI-Bone
|
Mar 18, 2020 | BUY |
Strong Buy
+37.7% avg upside
18 analysts
|
$27.00
41.71% Upside
|
+298.9% | · |
|
MDXG
MiMedx Group
|
Dec 06, 2018 | HOLD |
Strong Buy
+148.5% avg upside
17 analysts
|
— | +517.5% | · |
|
SINT
Sintx Technologies
|
Nov 11, 2016 | BUY |
Strong Buy
+356.9% avg upside
8 analysts
|
— | · | · |
|
ADMA
ADMA Biologics
|
Nov 06, 2015 | BUY |
Strong Buy
+10.9% avg upside
15 analysts
|
$1.00
89.83% Downside
|
-43.5% | · |
|
ISRG
Intuitive Surgical
|
Apr 19, 2013 | BUY |
Strong Buy
+19.9% avg upside
36 analysts
|
$636.00
58.95% Upside
|
-15.0% | · |
|
OFIX
Orthofix Medical
|
Apr 17, 2009 | SELL |
Buy
+174.3% avg upside
15 analysts
|
— | -115.2% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.